/
DCF Valuation
Base-case fair value
$51.71
Intrinsic $68.95 · 25% MOS
Current price: $8.54
Base-case summary
Our base-case DCF for Bioventus Inc. (BVS) projects 10 years of free cash flow growth at 20.0% for years 1–5 and 10.0% for years 6–10, anchored to 60.4% historical FCF growth, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from $101M in trailing free cash flow, this produces an intrinsic value of $68.95 per share. A 25% safety margin gives a fair value of $51.71, suggesting the stock is currently 506% undervalued against the $8.54 market price.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
$101M
Cash & equivalents
$36M
Total debt
$288M
Shares outstanding
70M